Petzinger Giselle M, Fisher Beth, Hogg Elizabeth, Abernathy Avery, Arevalo Pablo, Nixon Kerry, Jakowec Michael W
George and MaryLou Boone Parkinson's Disease and Movement Disorders Research Center, Department of Neurology, University of Southern California, Los Angeles, California.
J Neurosci Res. 2006 Feb 1;83(2):332-47. doi: 10.1002/jnr.20730.
The neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) provides an excellent opportunity to study repair and response to injury in the basal ganglia. Administration to mammals leads to the destruction of nigrostriatal dopaminergic neurons and depletion of striatal dopamine. In the squirrel monkey (Saimiri sciureus), MPTP-lesioning results in parkinsonian motor symptoms including bradykinesia, postural instability, and rigidity. Over time animals display motor behavioral recovery. To better understand this mechanism we employed a lesioning regimen of two or six subcutaneous injections of MPTP (2.0 mg/kg, free-base) to generate mild or moderate parkinsonism. Brain tissue was harvested at 6 weeks or 9 months after the last injection and analyzed for dopamine and its metabolites by high performance liquid chromatography (HPLC), and by immunohistochemical staining and Western immunoblotting for the expression of tyrosine hydroxylase (TH), dopamine transporter (DAT), and dopamine- and cAMP-responsive protein phosphatase of 32 kDa (DARPP-32), an effector molecule enriched in striatal medium spiny neurons. Several months after MPTP-lesioning, when squirrel monkeys displayed full motor behavioral recovery, striatal dopamine levels remained low with a greater return in the ventral striatum. This finding is consistent with other reports using neurotoxicant-lesioning models of the basal ganglia in rodents and other species of nonhuman primates. Elevated dopamine turnover ratio and decreased DAT expression appeared in early behavioral recovery at the 6-week time point in both mild- and moderate-parkinsonian monkeys. Tyrosine hydroxylase and DAT expression was increased in late stage recovery even within dopamine-depleted regions and supports sprouting. Altered DARPP-32 expression suggests a role of medium spiny neurons in recovery.
神经毒素1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)为研究基底神经节的损伤修复和反应提供了一个绝佳的机会。给哺乳动物注射MPTP会导致黑质纹状体多巴胺能神经元的破坏以及纹状体多巴胺的耗竭。在松鼠猴(Saimiri sciureus)中,MPTP损伤会导致帕金森氏运动症状,包括运动迟缓、姿势不稳和僵硬。随着时间的推移,动物会表现出运动行为的恢复。为了更好地理解这一机制,我们采用了皮下注射两次或六次MPTP(2.0 mg/kg,游离碱)的损伤方案,以产生轻度或中度帕金森症。在最后一次注射后的6周或9个月采集脑组织,通过高效液相色谱(HPLC)分析多巴胺及其代谢产物,并通过免疫组织化学染色和蛋白质免疫印迹法检测酪氨酸羟化酶(TH)、多巴胺转运体(DAT)和32 kDa多巴胺和cAMP反应性蛋白磷酸酶(DARPP-32)的表达,DARPP-32是一种在纹状体中等棘状神经元中富集的效应分子。MPTP损伤数月后,当松鼠猴表现出完全的运动行为恢复时,纹状体多巴胺水平仍然较低,腹侧纹状体的恢复程度更大。这一发现与其他使用啮齿动物和其他非人类灵长类动物基底神经节神经毒素损伤模型的报告一致。在轻度和中度帕金森症猴子的6周时间点,早期行为恢复时出现多巴胺周转率升高和DAT表达降低。即使在多巴胺耗竭区域,酪氨酸羟化酶和DAT表达在后期恢复时也会增加,并支持轴突发芽。DARPP-32表达的改变表明中等棘状神经元在恢复过程中发挥了作用。